Quantifying a Rare Disease in Administrative Data: The Example of Calciphylaxis
Calciphylaxis, a rare disease seen in chronic dialysis patients, is associated with significant morbidity and mortality. As is the case with other rare diseases, the precise epidemiology of calciphylaxis remains unknown. Absence of a unique International Classification of Diseases (ICD) code impedes its identification in large administrative databases such as the United States Renal Data System (USRDS) and hinders patient-oriented research. This study was designed to develop an algorithm to accurately identify cases of calciphylaxis and to examine its incidence and mortality.
DESIGN, PARTICIPANTS, AND MAIN MEASURES
Along with many other diagnoses, calciphylaxis is included in ICD-9 code 275.49, Other Disorders of Calcium Metabolism. Since calciphylaxis is the only disorder listed under this code that requires a skin biopsy for diagnosis, we theorized that simultaneous application of code 275.49 and skin biopsy procedure codes would accurately identify calciphylaxis cases. This novel algorithm was developed using the Partners Research Patient Data Registry (RPDR) (n = 11,451 chronic hemodialysis patients over study period January 2002 to December 2011) using natural language processing and review of medical and pathology records (the gold-standard strategy). We then applied this algorithm to the USRDS to investigate calciphylaxis incidence and mortality.
Comparison of our novel research strategy against the gold standard yielded: sensitivity 89.2 %, specificity 99.9 %, positive likelihood ratio 3,382.3, negative likelihood ratio 0.11, and area under the curve 0.96. Application of the algorithm to the USRDS identified 649 incident calciphylaxis cases over the study period. Although calciphylaxis is rare, its incidence has been increasing, with a major inflection point during 2006–2007, which corresponded with specific addition of calciphylaxis under code 275.49 in October 2006. Calciphylaxis incidence continued to rise even after limiting the study period to 2007 onwards (from 3.7 to 5.7 per 10,000 chronic hemodialysis patients; r = 0.91, p = 0.02). Mortality rates among calciphylaxis patients were noted to be 2.5–3 times higher than average mortality rates for chronic hemodialysis patients.
By developing and successfully applying a novel algorithm, we observed a significant increase in calciphylaxis incidence. Because calciphylaxis is associated with extremely high mortality, our study provides valuable information for future patient-oriented calciphylaxis research, and also serves as a template for investigating other rare diseases.
- Rogers, NM, Coates, PT (2008) Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 17: pp. 629-34 CrossRef
- Brandenburg, VM, Cozzolino, M, Ketteler, M (2011) Calciphylaxis: a still unmet challenge. J Nephrol 24: pp. 142-8 CrossRef
- Budisavljevic, MN, Cheek, D, Ploth, DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol 7: pp. 978-82
- Weenig, RH, Sewell, LD, Davis, MD, McCarthy, JT, Pittelkow, MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56: pp. 569-79 CrossRef
- Fine, A, Zacharias, J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61: pp. 2210-7 CrossRef
- Polizzotto, MN, Bryan, T, Ashby, MA, Martin, P (2006) Symptomatic management of calciphylaxis: a case series and review of the literature. J Pain Symptom Manag 32: pp. 186-90 CrossRef
- www.raredisease.info.nih.gov. www.raredisease.info.nih.gov (accessed May 17 2014).
- Selye, H, Gentile, G, Prioreschi, P (1961) Cutaneous molt induced by calciphylaxis in the rat. Science 134: pp. 1876-7 CrossRef
- Brandenburg, VM, Kramann, R, Specht, P, Ketteler, M (2012) Calciphylaxis in CKD and beyond. Nephrol Dial Transplant 27: pp. 1314-8 CrossRef
- www.usrds.org. 2013. www.usrds.org.
- Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a Research Patient Data Repository. AMIA Annu Symp Proc. 2006: 1044.
- www.cdc.gov/nchs/icd.htm. 2013. www.cdc.gov/nchs/icd.htm (accessed May 17,2014).
- Essary, LR, Wick, MR (2000) Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol 113: pp. 280-7 CrossRef
- www.ama-assn.org/go/cpt. 2013. www.ama-assn.org/go/cpt (accessed May 17,2014).
- Sulkowski, JP, Deans, KJ, Asti, L, Mattei, P, Minneci, PC (2013) Using the Pediatric Health Information System to study rare congenital pediatric surgical diseases: development of a cohort of esophageal atresia patients. J Pediatr Surg 48: pp. 1850-5 CrossRef
- Xia, Z, Secor, E, Chibnik, LB (2013) Modeling disease severity in multiple sclerosis using electronic health records. PLoS One 8: pp. e78927 CrossRef
- Denny, JC (2012) Chapter 13: Mining electronic health records in the genomics era. PLoS Comput Biol 8: pp. e1002823 CrossRef
- Murff, HJ, FitzHenry, F, Matheny, ME (2011) Automated identification of postoperative complications within an electronic medical record using natural language processing. JAMA 306: pp. 848-55 CrossRef
- Beaubrun, AC, Brookhart, MA, Sleath, B, Wang, L, Kshirsagar, AV (2013) Trends and variations in intravenous vitamin D use among hemodialysis patients in the United States. Ren Fail 35: pp. 1-8 CrossRef
- St Peter, WL, Li, Q, Liu, J (2009) Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4: pp. 354-60 CrossRef
- Weir, MA, Jain, AK, Gomes, T (2011) Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada. Am J Kidney Dis 57: pp. 357-9 CrossRef
- Shen, JI, Turakhia, MP, Winkelmayer, WC (2012) Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?. Curr Opin Nephrol Hypertens 21: pp. 600-6 CrossRef
- Kramer, HJ, Saranathan, A, Luke, A (2006) Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 17: pp. 1453-9 CrossRef
- Hart, RG, Eikelboom, JW, Ingram, AJ, Herzog, CA (2012) Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 8: pp. 569-78 CrossRef
- Nigwekar, SU, Bhan, I, Turchin, A (2013) Statin use and calcific uremic arteriolopathy: a matched case–control study. Am J Nephrol 37: pp. 325-32 CrossRef
- Hayashi, M, Takamatsu, I, Kanno, Y (2012) A case–control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27: pp. 1580-4 CrossRef
- Moe, SM, Chen, NX (2008) Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19: pp. 213-6 CrossRef
- Chatrou, ML, Winckers, K, Hackeng, TM, Reutelingsperger, CP, Schurgers, LJ (2012) Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev 26: pp. 155-66 CrossRef
- Neven, E, Schutter, TM, Behets, GJ, Gupta, A, D’Haese, PC (2011) Iron and vascular calcification. Is there a link?. Nephrol Dial Transplant 26: pp. 1137-45 CrossRef
- Chertow, GM, Block, GA, Correa-Rotter, R (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: pp. 2482-94 CrossRef
- Salmhofer, H, Franzen, M, Hitzl, W (2013) Multi-Modal Treatment Of Calciphylaxis With Sodium-Thiosulfate, Cinacalcet And Sevelamer Including Long-Term Data. Kidney Blood Press Res 37: pp. 346-59 CrossRef
- Nigwekar, SU, Wolf, M, Sterns, RH, Hix, JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 3: pp. 1139-43 CrossRef
- New, N, Mohandas, J, John, GT (2011) Calcific uremic arteriolopathy in peritoneal dialysis populations. Int J Nephrol 2011: pp. 982854 CrossRef
- Nigwekar, SU (2007) An unusual case of nonhealing leg ulcer in a diabetic patient. South Med J 100: pp. 851-2 CrossRef
- Brewster, UC, Perazella, MA (2005) Calcific uremic arteriolopathy in a transplanted kidney. Am J Med Sci 329: pp. 102-3 CrossRef
- Strazzula, L, Nigwekar, SU, Steele, D (2013) Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol 149: pp. 946-9 CrossRef
- Nigwekar, SU, Brunelli, SM, Meade, D, Wang, W, Hymes, J, Lacson, E (2013) Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 8: pp. 1162-70 CrossRef
- Quantifying a Rare Disease in Administrative Data: The Example of Calciphylaxis
Journal of General Internal Medicine
Volume 29, Issue 3 Supplement, pp 724-731
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- renal disease
- research design
- Industry Sectors
- Author Affiliations
- 1. Harvard Medical School, Boston, MA, USA
- 2. Massachusetts General Hospital, Boston, MA, USA
- 3. Minneapolis Medical Research Foundation, Minneapolis, MN, USA
- 4. Brigham and Women’s Hospital, Boston, MA, USA
- 5. University of Minnesota, Minneapolis, MN, USA
- 6. Hennepin County Medical Center, Minneapolis, MN, USA